Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HF2D
|
|||
| Drug Name |
PBF-1129
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1 | [1] | |
| Company |
Palobiofarma Barcelona, Spain
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2b receptor (ADORA2B) | Target Info | Antagonist | [1] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Alcoholism | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| Pathway Interaction Database | C-MYB transcription factor network | |||
| Reactome | Adenosine P1 receptors | |||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.